Exact Sciences reported quarterly profit-and-loss results Thursday that beat many analysts’ estimates. However, investors did not on the whole appear to be impressed, sending the company’s stock price more than 6 percent lower in after-hours trading.
Madison, WI-based Exact (NASDAQ: EXAS), is developing screening tests for a variety of cancers. Its flagship product is Cologuard, a stool-based DNA test for colorectal cancer screening.
Exact had previously disclosed several figures related to financial and business performance for the three-month period ending Dec. 31, but did not report full financial results until Thursday. The company’s fourth-quarter net loss was $21.8 million, or 18… Read more »
UNDERWRITERS AND PARTNERS